(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 February 2022 (24.02.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/040596 A1

(51) International Patent Classification:
A61K 47/60 (2017.01) *A61P 35/00* (2006.01)
A61K 47/68 (2017.01)

(21) International Application Number:
PCT/US2021/047009

(22) International Filing Date:
20 August 2021 (20.08.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/068,342 20 August 2020 (20.08.2020) US
63/118,365 25 November 2020 (25.11.2020) US

(71) Applicant: **AMBRX, INC.** [US/US]; 10975 North Torrey Pines Road, La Jolla, California 92037 (US).

(72) Inventors: **MOON, Sung-Ju**; 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **LEON, Brian**; 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **KANG, Mingchao**; 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **KNUDSEN, Nickolas**; 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **SAKAMURI, Sukumar**; 10975 North Torrey Pines Road, La Jolla, California 92037 (US). **TIAN, Feng**; 10975 North Torrey Pines Road, La Jolla, California 92037 (US).

(74) Agent: **TIAN, Feng**; WILSON SONSINI GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto, California 94304 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*


Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF

FIG. 1



Formula (I)



Formula (II)

(57) Abstract: Disclosed herein are TLR-agonists compounds, antibody-TLR agonist conjugates, pharmaceutical composition, and methods of use of such compounds or conjugates as therapeutics for treating a disease or condition such as cancer.

WO 2022/040596 A1